Giant Biogene Holding Future Growth
Future criteria checks 6/6
Giant Biogene Holding is forecasted to grow earnings and revenue by 31.8% and 29.7% per annum respectively. EPS is expected to grow by 26.8%. Return on equity is forecast to be 30.2% in 3 years.
Key information
31.8%
Earnings growth rate
26.8%
EPS growth rate
| Personal Products earnings growth | 16.2% |
| Revenue growth rate | 29.7% |
| Future return on equity | 30.2% |
| Analyst coverage | Good |
| Last updated | 04 May 2023 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 5,913 | 2,209 | N/A | 4,644 | 4 |
| 12/31/2024 | 4,383 | 1,723 | N/A | 1,670 | 6 |
| 12/31/2023 | 3,224 | 1,307 | N/A | 1,380 | 6 |
| 12/31/2019 | 957 | 552 | 571 | 656 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2367's forecast earnings growth (31.8% per year) is above the savings rate (1.8%).
Earnings vs Market: 2367's earnings (31.8% per year) are forecast to grow faster than the Hong Kong market (15.2% per year).
High Growth Earnings: 2367's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2367's revenue (29.7% per year) is forecast to grow faster than the Hong Kong market (9% per year).
High Growth Revenue: 2367's revenue (29.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2367's Return on Equity is forecast to be high in 3 years time (30.2%)